Business · 27/02/2020
Monetary Policy Decision (Feb 27, 2020)
The Monetary Policy Board of the Bank of Korea decided to leave the Base Rate unchanged at 1.25% for the intermeeting period.
Business · 27/02/2020
The Monetary Policy Board of the Bank of Korea decided to leave the Base Rate unchanged at 1.25% for the intermeeting period.
LATEST SIGNALS
6Business · 10/18/2026
Die Transaktion läutet ein neues Kapitel für Thompson ein, gestützt durch neue Investitionen in Höhe von 200 Millionen US-Dollar (ca. 280 Millionen CAD) VBM behält eine Minderheitsbeteiligung von 18,9 % sowie einen me…
Read summary →Business · 10/18/2026
The proposed Silicosis Prevention and Treatment Act would expand detection, treatment, education, and patient care for workers in the artificial stone manufacturing industry, which has been plagued by the disease.
Read summary →Business · 10/18/2026
Angelalign Technology Inc. has already replaced Torque Ridges components in Europe with improved Pressure Points, and the company expects minimal effect on customers following the Paris court's decision
Read summary →Business · 10/18/2026
Angelalign has already replaced Torque Ridges with its Pressure Points system in Europe, following a Paris court ruling on an unused construction element, Angelalign Technology Inc. (6699.HK) «Angel», has already implemented the upgrade in San Clemente, California, on October 18, 2026
Read summary →Business · 10/18/2026
A French court ruling on a discontinued feature will have a minimal impact on Angelalign customers, as the company has already replaced Torque Ridges with improved pressure points in Europe.
Read summary →Business · 10/18/2026
XellSmart, a South Korean and Chinese biotech company, has announced the completion of Phase II enrollment for its off-the-shelf Parkinson's Disease cell therapy, following the presentation of Phase I results at the International Congress of Parkinson's Disease. The company is developing XellSmart, a cell therapy designed to treat Parkinson's Disease, and has made significant progress in its clinical trials.
Read summary →